Decoding trends in mRNA vaccine research: A comprehensive bibliometric study

References

• Peck M, Gacic-Dobo M, Diallo MS, Nedelec Y, Sodha SS, Wallace AS. Global routine vaccination coverage. MMWR Morb Mortal Wkly Rep. 2018;68(42):937–18. doi:10.15585/mmwr.mm6842a1.
   Web of Science ®Google Scholar
• Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities. Vaccines. 2021;9(12):1490. doi:10.3390/vaccines9121490.
   PubMed Web of Science ®Google Scholar
• Xu S, Yang K, Li R, Zhang L. mRNA vaccine era–mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21(18):6582. doi:10.3390/ijms21186582.
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–20. doi:10.1016/S0140-6736(17)31665-3.
   PubMed Web of Science ®Google Scholar
• Granot-Matok Y, Ezra A, Ramishetti S, Sharma P, Naidu GS, Benhar I, Peer D. Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors. THERANOSTICS. 2023;13(11):3497–508. doi:10.7150/thno.82228.
   PubMed Web of Science ®Google Scholar
• de Miguel AG, Gil-Prieto R. Vaccination strategies against SARS-CoV-2: General impact on the development of the pandemic. Revista Espanola De Quimioterapia. 2021;34(Suppl 1):60–2. doi:10.37201/req/s01.18.2021.
   PubMedGoogle Scholar
• Guler AT, Waaijer CJ, Palmblad M. Scientific workflows for bibliometrics. Scientometrics. 2016;107(2):385–98. doi:10.1007/s11192-016-1885-6.
   PubMed Web of Science ®Google Scholar
• Radu AF, Bungau SG, Negru PA, Marcu MF, Andronie-Cioara FL. In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy. Biomed Pharmacother. 2022;154:113614. doi:10.1016/j.biopha.2022.113614.
   PubMed Web of Science ®Google Scholar
• Ma C, Su H, Li H. Global research trends on prostate diseases and erectile dysfunction: a bibliometric and visualized study. Front Oncol. 2020;10:627891. doi:10.3389/fonc.2020.627891.
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593–608. doi:10.1517/14712598.2012.674507.
   PubMed Web of Science ®Google Scholar
• Zheng B, Kuang Y, Yuan D, Huang H, Liu S. The research landscape of immunology research in spinal cord injury from 2012 to 2022. Jor Spine. 2023;6(3):e1261. doi:10.1002/jsp2.1261.
   PubMedGoogle Scholar
• Sun J, Zhao H, Fu L, Cui J, Yang Y. Global trends and research progress of photodynamic therapy in skin cancer: a bibliometric analysis and literature review. Clin Cosmet Investig Dermatol. 2023;16:479–98. doi:10.2147/CCID.S401206.
   PubMed Web of Science ®Google Scholar
• Shen Z, Wu H, Chen Z, Hu J, Pan J, Kong J. The global research of artificial intelligence on prostate cancer: a 22-year bibliometric analysis. Front Oncol. 2022;12:843735. doi:10.3389/fonc.2022.843735.
   PubMed Web of Science ®Google Scholar
• Goswami GG, Labib T. Modeling COVID-19 transmission dynamics: a bibliometric review. Int J Environl Res Public Health. 2022;19(21):14143. doi:10.3390/ijerph192114143.
   PubMed Web of Science ®Google Scholar
• Oh KE, Flaherty GT. Travel medicine research in the new millennium: A bibliometric analysis of articles published in travel medicine and infectious disease, 2003-2019. Travel Med Infect Dis. 2020;33:101549. doi:10.1016/j.tmaid.2019.101549.
   PubMed Web of Science ®Google Scholar
• Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959–75. doi:10.1016/j.joi.2017.08.007.
   Web of Science ®Google Scholar
• Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: A new method of publication portfolio analysis. J Assoc Inf Sci Technol. 2014;65(2):334–51. doi:10.1002/asi.22968.
   Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. et al. Safety and efficacy of the BNT162b2 mRNA covid-19vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther. 2020;28(7):1569–84. doi:10.1016/j.ymthe.2020.04.018.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against h10n8 and h7n9 influenza viruses. Mol Ther. 2017;25(6):1316–27. doi:10.1016/j.ymthe.2017.03.035.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower Doses. Mol Ther. 2018;26(2):446–55. doi:10.1016/j.ymthe.2017.11.017.
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. NATURE. 2012;481(7379):81–U88. doi:10.1038/nature10660.
   Web of Science ®Google Scholar
• Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S. et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–31. doi:10.1021/acscentsci.0c00272.
   PubMed Web of Science ®Google Scholar
• Nane GF, Robinson-Garcia N, van Schalkwyk F, Torres-Salinas D. COVID-19 and the scientific publishing system: growth, open access and scientific fields. Scientometrics. 2023;128(1):345–62. doi:10.1007/s11192-022-04536-x.
   PubMed Web of Science ®Google Scholar
• Van Der Wende M. International academic mobility: Towards a concentration of the minds in europe. Eur Rev. 2015;23(S1):70–88. doi:10.1017/s1062798714000799.
   Google Scholar
• Aygün I, Barciszewski J. The forerunners and successful partnerships behind the BioNTech mRNA vaccine. J Appl Genet. 2023;65(1):47–55. doi:10.1007/s13353-023-00793-5.
   PubMed Web of Science ®Google Scholar
• Lindsay KE, Bhosle SM, Zurla C, Beyersdorf J, Rogers KA, Vanover D, Xiao P, Araínga M, Shirreff LM, Pitard B. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nat Biomed Eng. 2019;3(5):371–80. doi:10.1038/s41551-019-0378-3.
   PubMed Web of Science ®Google Scholar
• Selby LI, Cortez-Jugo CM, Such GK, Johnston APR. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. Wiley Interdisciplinary Reviews-Nanomedicine And Nanobiotechnology. 2017;9(5). doi:10.1002/wnan.1452.
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2–12. doi:10.1021/acs.accounts.1c00544.
   PubMed Web of Science ®Google Scholar
• Salleh MZ, Norazmi MN, Deris ZZ. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ. 2022;10:e13083. doi:10.7717/peerj.13083.
   PubMed Web of Science ®Google Scholar
• Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, John S, Hassett K, Yuzhakov O, Bahl K. et al. Efficient Targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol Ther. 2017;25(12):2635–47. doi:10.1016/j.ymthe.2017.08.006.
   PubMed Web of Science ®Google Scholar
• Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75. doi:10.1016/j.immuni.2005.06.008.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological Stability. Mol Ther. 2008;16(11):1833–40. doi:10.1038/mt.2008.200.
   PubMed Web of Science ®Google Scholar
• Zhang ZK, Ohto U, Shibata T, Krayukhina E, Taoka M, Yamauchi Y, Tanji H, Isobe T, Uchiyama S, Miyake K. et al. Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded rNA. Immunity. 2016;45(4):737–48. doi:10.1016/j.immuni.2016.09.011.
   PubMed Web of Science ®Google Scholar
• Tanji H, Ohto U, Shibata T, Taoka M, Yamauchi Y, Isobe T, Miyake K, Shimizu T. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nature Structural & Molecular Biology. 2015;22(2):109–15. doi:10.1038/nsmb.2943.
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, Karikó K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38(17):5884–92. doi:10.1093/nar/gkq347.
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Kariko K. Nucleoside modifications in RNA limit activation of 2-5-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011;39(21):9329–38. doi:10.1093/nar/gkr586.
   PubMed Web of Science ®Google Scholar
• Mu X, Greenwald E, Ahmad S, Hur S. An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res. 2018;46(10):5239–49. doi:10.1093/nar/gky177.
   PubMed Web of Science ®Google Scholar
• Pardi N, Muramatsu H, Weissman D, Kariko K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol. 2013;969:29–42. doi:10.1007/978-1-62703-260-5_2.
   PubMedGoogle Scholar
• Henderson JM, Ujita A, Hill E, Yousif‐Rosales S, Smith C, Ko N, McReynolds T, Cabral CR, Escamilla‐Powers JR, Houston ME. et al. Cap 1 messenger RNA synthesis with Co-transcriptional CleanCap® Analog by in vitro transcription. Curr Protocol. 2021;1(2):e39. doi:10.1002/cpz1.39.
   PubMedGoogle Scholar
• Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–88. doi:10.1084/jem.20171450.
   PubMed Web of Science ®Google Scholar
• Tam HH, Melo MB, Kang M, Pelet JM, Ruda VM, Foley MH, Hu JK, Kumari S, Crampton J, Baldeon AD. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci USA. 2016;113(43):6639–48. doi:10.1073/pnas.1606050113.
   PubMed Web of Science ®Google Scholar
• Li Y, Ma X, Yue Y, Zhang K, Cheng K, Feng Q, Ma N, Liang J, Zhang T, Zhang L. et al. Rapid surface display of mRNA antigens by bacteria-derived outer membrane vesicles for a personalized tumor vaccine. Adv Mater. 2022;34(20). doi:10.1002/adma.202109984.
   Web of Science ®Google Scholar
• Niazi SK. Making COVID-19 mRNA vaccines accessible: challenges resolved. Expert Rev Vaccines. 2022;21(9):1163–76. doi:10.1080/14760584.2022.2089121.
   PubMed Web of Science ®Google Scholar
• Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416. doi:10.1016/j.addr.2022.114416.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Z, Wang L, Chen K, Wang Y. mRNA vaccine delivery carrier useful for preparing mRNA vaccine and medicine for preventing and/or treating tumors, viral pneumonia or related diseases, is prepared using polyethylene glycol-polyphosphate block copolymer and cationic lipid. CN116763933-A.
   Google Scholar
• Xia X, Zhang H, Wu J, You X. mRNA vaccine delivery vector, is lipid polymer, obtained by reacting polyamidoamine dendrimer with 1,2-epoxydodecane. CN110448695-A; CN110448695-B.
   Google Scholar
• Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles–From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. Acs Nano. 2021;15(11):16982–7015. doi:10.1021/acsnano.1c04996.
   PubMed Web of Science ®Google Scholar
• Ji AF, Xu M, Pan Y, Diao L, Ma L, Qian L, Cheng J, Liu M. Lipid microparticles show similar efficacy with lipid nanoparticles in delivering mRNA and preventing cancer. Pharm Res. 2023;40(1):265–79. doi:10.1007/s11095-022-03445-1.
   PubMed Web of Science ®Google Scholar
• Aldosari BN, Alfagih IM, Almurshedi AS. Lipid Nanoparticles as delivery systems for RNA-Based vaccines. Pharmaceutics. 2021;13(2):206. doi:10.3390/pharmaceutics13020206.
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710–28. doi:10.1016/j.ymthe.2019.02.012.
   PubMed Web of Science ®Google Scholar
• Shobaki N, Sato Y, Harashima H. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting. Int J Nanomed. 2018;13:8395–410. doi:10.2147/IJN.S188016.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat Nanotechnol. 2020;15(4):313–20. doi:10.1038/s41565-020-0669-6.
   PubMed Web of Science ®Google Scholar
• Guevara ML, Persano S, Persano F. Lipid-Based vectors for therapeutic mRNA-Based anti-cancer vaccines. Curr Pharm Des. 2019;25(13):1443–54. doi:10.2174/1381612825666190619150221.
   PubMed Web of Science ®Google Scholar
• Arangoa MA, Düzgünes N, de Ilarduya CT. Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin-lipoplexes. Gene Ther. 2003;10(1):5–14. doi:10.1038/sj.gt.3301840.
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ. et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329–40. doi:10.1016/s1473-3099(21)00677.
   PubMed Web of Science ®Google Scholar
• Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL, Dorkin JR. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357–64. doi:10.1038/mt.2010.85.
   PubMed Web of Science ®Google Scholar
• Ren J, Cao Y, Li L, Wang X, Lu H, Yang J, Wang S. Self-assembled polymeric micelle as a novel mRNA delivery carrier. J Controlled Release. 2021;338:537–47. doi:10.1016/j.jconrel.2021.08.061.
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. NATURE. 2023;618(7963):144–50. doi:10.1038/s41586-023-06063-y.
   PubMed Web of Science ®Google Scholar
• Luo F, Zheng L, Hu Y, Liu S, Wang Y, Xiong Z, Hu X, Tan F. Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP). Front Microbiol. 2017;8:605. doi:10.3389/fmicb.2017.00605.
   PubMed Web of Science ®Google Scholar
• https://investors.modernatx.com/news, 2023).
   Google Scholar
• He Q, Gao H, Tan D, Zhang H, Wang J. Z. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm Sin B. 2022;12(7):2969–89. doi:10.1016/j.apsb.2022.03.011.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, Huang L. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast Cancer. Mol Ther. 2018;26(1):45–55. doi:10.1016/j.ymthe.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Krishna S, Anderson KS. T-Cell epitope discovery for therapeutic cancer vaccines. Methods Mol Biol. 2016;1403:779–96. doi:10.1007/978-1-4939-3387-7_45.
   PubMedGoogle Scholar
• Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U. et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011;71(19):6132–42. doi:10.1158/0008-5472.CAN-11-0291.
   PubMed Web of Science ®Google Scholar
• Li JY, Wu Y, Xiang J, Wang H, Zhuang Q, Wei T, Cao Z, Gu Q, Liu Z, Peng R. et al. Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines. Chem Eng J. 2023;456:456. doi:10.1016/j.cej.2022.140930.
   Web of Science ®Google Scholar
• Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G. Evolution and progress of mRNA vaccines in the treatment of melanoma: Future prospects. Nato Adv Sci Inst Se. 2023;11(3):636. doi:10.3390/vaccines11030636.
   Google Scholar
• Islam MA, Rice J, Reesor E, Zope H, Tao W, Lim M, Ding J, Chen Y, Aduluso D, Zetter BR. et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. BIOMATERIALS. 2021;266:120431. doi:10.1016/j.biomaterials.2020.120431.
   PubMed Web of Science ®Google Scholar
• Zhou W, Jiang L, Liao S, Wu F, Yang G, Hou L, Liu L, Pan X, Jia W, Zhang Y. et al. Vaccines’ new Era-RNA Vaccine. Viruses. 2023;15(8):1760. doi:10.3390/v15081760.
   PubMed Web of Science ®Google Scholar
• Chen P, Shi X, He W, Zhong G, Tang Y, Wang H, Zhang P. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Hum Vaccines Immunother. 2022;18(1):2040330. doi:10.1080/21645515.2022.2040330.
   PubMed Web of Science ®Google Scholar
• Rice SM, Ferree SD, Mesinkovska NA, Kourosh AS. The art of prevention: COVID-19 vaccine preparedness for the dermatologist. International Journal of Women’s Dermatology. 2021;7(2):209–12. doi:10.1016/j.ijwd.2021.01.007.
   PubMedGoogle Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325(8):780–1. doi:10.1001/jama.2021.0600.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhao T, Zhao W, Shao A, Zhao H, Ma W, Gong Y, Zeng X, Weng C, Bu L. et al. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques. Emerging Microbes Infect. 2024;13:2309985. doi:10.1080/22221751.2024.2309985.
   PubMed Web of Science ®Google Scholar
• Kung F, Kaur S, Smith AA, Yang X, Wilder CN, Sharma K, Buyuktanir O, Pal U. A Borrelia burgdorferi surface-exposed transmembrane protein lacking detectable immune responses supports pathogen persistence and constitutes a vaccine target. J Infect Dis. 2016;213(11):1786–95. doi:10.1093/infdis/jiw013.
   PubMed Web of Science ®Google Scholar
• Duthie MS, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J, Hsu F-C, Stinchcomb DT, Reed SG. Heterologous immunization with defined RNA and subunit vaccines enhances T cell responses that protect against leishmania donovani. Front Immunol. 2018;9:2420. doi:10.3389/fimmu.2018.02420.
   PubMed Web of Science ®Google Scholar
• Versteeg L, Almutairi MM, Hotez PJ, Pollet J. Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines. 2019;7(4):122. doi:10.3390/vaccines7040122.
   Web of Science ®Google Scholar
• Saunders KO, Pardi N, Parks R, Santra S, Mu Z, Sutherland L, Scearce R, Barr M, Eaton A, Hernandez G. et al. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. NPJ Vaccines. 2021;6(1). doi:10.1038/s41541-021-00307-6.
   Web of Science ®Google Scholar
• Paloncyová M, Cechová P, Srejber M, Kührová P, Otyepka M. Role of ionizable lipids in SARS-CoV-2 vaccines as revealed by molecular dynamics simulations: from membrane structure to interaction with mRNA fragments. J Phys Chem Lett. 2021;12(45):11199–205. doi:10.1021/acs.jpclett.1c03109.
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–38. doi:10.1038/s41573-021-00283-5.
   PubMed Web of Science ®Google Scholar
• Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376–81. doi:10.1016/j.ijid.2021.04.047.
   PubMed Web of Science ®Google Scholar
• Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022;40(40):5798–805. doi:10.1016/j.vaccine.2022.08.036.
   PubMed Web of Science ®Google Scholar
• Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, Alderei AS, El Eissaee HN, Al Ketbi RM, Al Shamsi NS. et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE—An observational study. Front Public Health. 2022;10:876336. doi:10.3389/fpubh.2022.876336.
   PubMed Web of Science ®Google Scholar
• Ng SC, Peng Y, Zhang L, Mok CK, Zhao S, Li A, Ching JY, Liu Y, Yan S, Chan DLS. et al. Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut. 2022;71(6):1106–16. doi:10.1136/gutjnl-2021-326563.
   PubMed Web of Science ®Google Scholar
• Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz LM, Berger H, Petschenka J. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–53. doi:10.1126/science.aay3638.
   PubMed Web of Science ®Google Scholar
• Furlan R. A Tolerizing mRNA Vaccine against Autoimmunity? Mol Ther. 2021;29(3):896–7. doi:10.1016/j.ymthe.2021.02.003.
   PubMed Web of Science ®Google Scholar